Results from phase two clinical trials at UT Southwestern Medical Center showed that a suspension of gold nanocrystals taken daily by patients with multiple sclerosis (MS) and Parkinson’s disease (PD) significantly reversed deficits of metabolites linked to energy activity in the brain and resulted in functional improvements.
This whole thing stinks of advertising. They use a sample size of 24 people. The results are underwhelming: “Each disease cohort concordantly demonstrated increases in the NAD+/NADH ratio but did not reach significance individually” (“when we massaged the numbers, the result we wanted popped out”). Looking at the graphs, it looks like the upper half (highest baselines) of the patients worsened over the 12 week study.
My favorite lines?
“The objective of the Phase 2 REPAIR-MS and REPAIR-PD clinical trials was to investigate the effects of CNM-Au8” and “CNM-Au8® is a suspension of faceted, clean-surfaced gold nanocrystals” and course:
Here’s the journal article itself
This whole thing stinks of advertising. They use a sample size of 24 people. The results are underwhelming: “Each disease cohort concordantly demonstrated increases in the NAD+/NADH ratio but did not reach significance individually” (“when we massaged the numbers, the result we wanted popped out”). Looking at the graphs, it looks like the upper half (highest baselines) of the patients worsened over the 12 week study.
My favorite lines?
“The objective of the Phase 2 REPAIR-MS and REPAIR-PD clinical trials was to investigate the effects of CNM-Au8” and “CNM-Au8® is a suspension of faceted, clean-surfaced gold nanocrystals” and course:
“Clene Nanomedicine, Inc., funded this study.”